



6 February 2023

ASX ANNOUNCEMENT

Follow up to the “New Version NCCN Guidelines® for Breast Cancer” ASX Release

ImpediMed Limited (ASX:IPD), today announced that the National Comprehensive Cancer Network® (NCCN) released meeting notes associated with the recently released Version 1.2023 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer on 3 February 2023 in the US. These meeting notes were published subsequent to the NCCN Breast Cancer Guidelines as reported by the Company in the recent ASX release of 30 January 2023. The meeting notes give insight to the NCCN Breast Cancer Panel’s decision.

The Panel Discussion/References were as follows:

The panel consensus was not to make any changes as there is a link saying “Educate, monitor, and refer for lymphedema management, see NCCN Guidelines for Survivorship: Lymphedema” The NCCN Guidelines for Survivorship cover lymphedema management.

As noted in the 30 January 2023 ASX release, the section on lymphoedema remains unchanged, but, importantly, the references linking the Breast Cancer guidelines directly to the Survivorship guidelines remain.

As noted previously, a second independent submission was also made to the NCCN Survivorship Panel. The Survivorship Panel includes a lymphoedema subpanel, so there will be a clear understanding of lymphoedema and the unique solution bioimpedance spectroscopy (BIS) offers cancer survivors.

The NCCN Survivorship Panel met in October 2022 to review all submissions and vote on updates to the guidelines. A new version of the NCCN Guidelines for Survivorship is still pending. Based on the timing of recent releases, the Survivorship guidelines would likely be published before ImpediMed’s Q3 2023 results are released in April 2023.

Refer to the 30 January 2023 ASX Announcement “New Version of NCCN Guidelines® for Breast Cancer” for more details, including the Company’s focus on its dual path to reimbursement.

Approved for release by Managing Director and CEO, Mr Richard Valencia.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.